The Unique Role of the Community Pharmacist in the Management of Moderate-to-Severe Atopic Dermatitis in the Pediatric Population

A Midday Symposium conducted at the 2018 ASHP Midyear Clinical Meeting and Exhibition

View Activity

FACULTY

Lindsay Strowd, MD, FAAD
Assistant Professor of Dermatology
Wake Forest Baptist Health
Winston-Salem, NC

Geoffrey C. Wall, PharmD, FCCP, BCPS
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Consulting Partner
Medical Intelligence Group, PLLC
Des Moines, IA

PROGRAM OVERVIEW

This online activity will cover the pathophysiology of atopic dermatitis, best practices for severity assessment and diagnosis, current and emerging therapeutic agents, and long-term decision-making for individualized care.

TARGET AUDIENCE

This activity is intended for US-based pharmacists involved in the management of pediatric patients with AD.

LEARNING OBJECTIVES

Upon completion of this enduring activity, participants will be able to:

  • Describe recent pathophysiological findings in AD that have informed the selection of new therapeutic targets
  • Identify best practices for severity assessment and diagnosis of moderate-to-severe AD in pediatric patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden
  • Review the clinical profiles and mechanisms of action of the new and emerging targeted agents for the treatment of pediatric patients with AD
  • Explain how different comorbidities and adherence barriers play a role in the choice of treatment regimens for pediatric patients with AD
  • Discuss the benefits of patient-centered health care management teams for pediatric patients with AD and the respective roles of team members

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

PHARMACY CREDIT INFORMAITON

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedLearning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this onlne activity for a maximum of 1.5 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
UAN: Pharmacists: JA4008163-9999-18-051-L04-P; Pharmacy Technician: JA4008163-9999-18-051-L04-T

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of oncology patients.
Credits: 1 ANCC Contact Hour(s)
ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded a maximum of 1 contact hour(s) of continuing nursing education of RNs and APNs.

ONCC RECERTIFICATION POINTS

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Strowd is a Speakers Bureau member for Sanofi Genzyme.
Dr. Wall is a Speakers Bureau member for Janssen, BI and LaJolla Pharmaceutials.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshiokpekhai MS, PharmD, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture Dr. Reddy may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

AMERICANS WITH DISABILITY ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the online event at info@medlearninggroup.com

RELEASE DATE: January 3, 2019

EXPIRATION DATE: January 3, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.